GGrantScoutHQCreate alert
OPENVerified record

Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in

Funding
See official notice
Deadline
September 26, 2028
Status
OPEN
Category
Health & Medical
Opens
November 26, 2025
Directory link check
October 27, 2026

About this opportunity

This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

Eligibility recorded

Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base. For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant types

Focus areas

Health

Recorded notice evidence

What to verify for Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Applicant evidence

  • Applicant type: State governments
  • Applicant type: County governments
  • Applicant type: City or township governments
  • Applicant type: Special district governments
  • Applicant type: Independent school districts
  • Applicant type: Public and state-controlled institutions of higher education
  • Applicant type: Federally recognized tribal governments
  • Applicant type: Native American tribal organizations

Opportunity boundaries

  • Recorded funding: See official notice
  • Recorded deadline: September 26, 2028; confirm the closing time.
  • Recorded focus: Health
Fields to verify directly: funding amount. A missing directory value does not remove a restriction.
Connect every eligibility claim, registration, attachment and deadline to the current notice. Open the specific official notice →

Application checklist

How to evaluate and apply for Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

Use this record for discovery, then connect every requirement and date to the current official notice and its amendments.

Recorded applicant fit

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and state-controlled institutions of higher education

Recorded geography

No structured geographic scope is recorded.

Recorded deadline

September 26, 2028 — confirm the closing time.

Eligibility summary: Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.gov/) for assistance in determining the RCDC funding base. For Renewal (Type 2) applications, an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions. However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources). Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters.cancer.gov/sites/default/files/PeerReviewFundingOrganizations.pdfNOTE: New (Type 1) applications cannot request evaluation for comprehensiveness status. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Recorded focus: Health

1Confirm fitMatch entity type, location, project scope, exclusions and cost share.
2Read the noticeCollect amendments, budget rules, attachments and portal instructions.
3Plan timingRecord the funder’s time zone, registrations and internal review dates.
4Submit officiallyUse the funder’s route and save the submission confirmation.

Official sources

Directory link check: October 27, 2026. Always recheck the live notice before relying on it.

Continue researching

Related current grants

All Health & Medical grants →
OPENHealth & Medical

OJJDP FY 2026 Juvenile Drug Treatment Court Program

Office of Juvenile Justice Delinquency Prevention

This is a notice of funding opportunity (NOFO) for the OJJDP FY 2026 Juvenile Drug Treatment Court Program. This opportunity will support states, state and local courts, units of local government, and federally recognized Tribal governments to implement new or enhance existing juvenile drug treatmen

Deadline
Oct 30, 2026
Funding
Estimated total program funding: $4,000,000
Check fit and official source →
OPENHealth & Medical

BJA FY 2026 Adult Treatment Court Program

Bureau of Justice Assistance

This is a notice of funding opportunity (NOFO) for the BJA FY2026 Adult Treatment Court Program. This opportunity supports the implementation and enhancement of Adult Treatment Court (ATC) operations to prevent overdoses and reduce the use of opioids, stimulants, and other substances by high-risk/hi

Deadline
Oct 31, 2026
Funding
Up to $2,500,000
Check fit and official source →
OPENHealth & Medical

HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)

National Institutes of Health

The NIH Helping to End Addiction Long-term® (HEAL) Initiative is releasing this Notice of Funding Opportunity (NOFO) to support a phased mechanistic clinical research program focusing on understudied biological mechanisms that drive joint pain. The phased projects supported by this program (of

Deadline
Oct 31, 2026
Funding
See official notice
Check fit and official source →
OPENHealth & Medical

GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)

National Institutes of Health

The Genomics Research to Elucidate the Genetics of Rare Diseases:innovation (GREGoRi) initiative seeks to accelerate a paradigm shift in rare disease diagnosis by reimagining the tools, molecular technologies and analytical approaches used to identify the causal gene(s) and/or variant(s) underlying

Deadline
Oct 31, 2026
Funding
Estimated total program funding: $2,000,000
Check fit and official source →